Actwatch Study Reference Document Thailand 2016
Total Page:16
File Type:pdf, Size:1020Kb
Evidence for Malaria Medicines Policy ACTwatch Study Reference Document Thailand 2016 www.ACTwatch.info Copyright © Population Services International (PSI). All rights reserved. 3 August 2016 Suggested citation ACTwatch Group and Population Services International/Thailand. (2016). ACTwatch Study Reference Document: Thailand Outlet Survey Findings 2016. Washington DC: PSI. Contact Dr. Megan Littrell Dr. Sanchai Chasombat ACTwatch Principal Investigator Deputy Director, Bureau of Vector Borne Disease PSI | 1120 19th St NW Suite 600 Thailand Ministry of Public Health Washington DC 20036 88/21 Tiwanon Road, Tambon Taladkhwan [email protected] Amphoe Muang, Nonthaburi 11000 +66 (0) 2-590-3132 [email protected] Acknowledgements ACTwatch is funded by the Bill and Melinda Gates Foundation, UNITAID, and the UK Department for International Development. This study was implemented by Population Services International (PSI). PSI Thailand Ipsos (Thailand), Ltd. Interpreters Alex Duke Pattama Jomsiriwattana Supanapchai Niyomrat Pirunya Panpromma Wilasinee Katenoi Chonnikarn Chattong Kullannit Poonsap Chirat Nopsert Yaowalak Jittakoat Chutinan Nateerattana Sukanya Moolkanya Gene Hornett Sirinee Limpiphitakasame Chatchapon Pongkunawut Benjarat Mahasukkanon Prompong Ungcharoen Aruntorn Rabpornpha Thailand NMCP Wantanee Wutikit Prowpimol Phetppreedeepong Dr. Sanchai Chasombat Tanawat Keepbongkod Sukanya BanJongpru Sunsanee Rojanapanus Saranrach Numsarapadnuek Dowpaka Patan Theerayot Kop-asa Photchanee Sae-tang Thiatjima Mekariyaset Rachaneekorn Maneesiri Jarouyporn Jantajak Pitoon Phuongchan Tanayut Poykhuntod Santana Klinhom ACTwatch Team Patchuda Thammawong Ratchanee Meemungkao Anna Fulton Surapong Siriseaw Supachal Noola Rachel Thompson Saowanee Tumpoung Sumet Lanworng Dr. Asawin Likhitsup Gorravik Raveekittikhun Bunikar Kasiongkram Kevin Duff Thirawut Namtiyanon Ratthanan Putthasuk Andrew Andrada Oraphan Chantham Witthayakun KhunKham Erick Auko Pornlaphat Limprakan Sudarat Hannarong Dr. Katie Bates Chonlatee Phaeckhumthod Butsayarin Lesing Dr. Desmond Chavasse Waraporn Soyai Niroot Hannarong Keith Esch Sarapee Chaiyasan Khonakorn Cayaso Tarryn Haslam Patchanee Labegban Chatpol Phongsai Catherine Hurley Montatip Thongnapa Paweena Aungphang Dr. Beth Kangwana Khanita Rattanajaratwong Ruangthip Charoenphan Gloria Kigo Khatesiree Poonsap Kritsada Vanichayakul Dr. Megan Littrell Stayu Pongsamana Rattanakul Suaysri Dr. Kathryn O’Connell Wanicha Waosamniang Kongsun Nakwan Julius Ngigi Chanowane Kar Chintana Nakhwan Ricki Orford Natthamon Larnvong Ruttikan Moonsup Stephen Poyer Naruporn Saengor Gunrada Wichatorn Dr. Justin Rahariniaina Ratree Noisong Pimpilai Tanadol Christina Riley Kamollux Yano Chinnarod Rattanajaratwong Dr. Andria Rusk Metha Sanchan Sreeya Thammarak Julianna Smith Jiraphat Sasen Parichat Kaewaroon Kate Thanel Chutiphon Kawsaoat Cynthia Whitman Anchalee Chairat www.ACTwatch.info Page 1 Table of Contents LIST OF TABLES ................................................................................................................................................... 3 LIST OF FIGURES ................................................................................................................................................. 4 DEFINITIONS....................................................................................................................................................... 3 INTRODUCTION .................................................................................................................................................. 5 SUMMARY OF METHODS AND DATA COLLECTION ........................................................................................... 7 SUMMARY OF KEY FINDINGS ........................................................................................................................... 10 RESULTS: CORE INDICATORS............................................................................................................................ 29 ANNEX 1: ACTWATCH BACKGROUND .............................................................................................................. 47 ANNEX 2: THAILAND BACKGROUND ................................................................................................................ 50 ANNEX 3: OUTLET SURVEY METHODS ............................................................................................................. 56 ANNEX 4: SAMPLED SUB-DISTRICTS ................................................................................................................ 60 ANNEX 5: DETAILED SAMPLE DESCRIPTION .................................................................................................... 64 ANNEX 6: QUESTIONNAIRE .............................................................................................................................. 67 ANNEX 7: ANTIMALARIAL REFERENCE ............................................................................................................. 93 ANNEX 8: RDT REFERENCE ............................................................................................................................... 97 ANNEX 9. SAMPLING WEIGHTS........................................................................................................................ 99 ANNEX 10: INDICATOR DEFINITIONS ............................................................................................................. 101 ANNEX 11. ADULT EQUIVALENT TREATMENT DOSE (AETD) ......................................................................... 107 www.ACTwatch.info Page 2 List of Table s Table 1: Outlet types screened and audited ......................................................................................................... 29 Table 2: Antimalarial and malaria blood testing market composition ..................................................................... 30 Table 3: Availability of malaria testing and treatment, among all screened outlets ................................................. 31 Table 4: Availability of malaria testing and treatment, among outlets stocking at least one antimalarial .................. 35 Table 5: Provision of malaria blood testing and antimalarials in the past week, among outlets with testing/antimalarials available ..................................................................................................................... 39 Table 6: Malaria blood testing market share......................................................................................................... 42 Table 7: Malaria blood testing market share within outlet type ............................................................................. 43 Table 8: Provider antimalarial treatment knowledge, by outlet type ...................................................................... 44 Annex Table X1: Sampled sub-districts ........................................................................................................................... 60 Table X2: Detailed sample description ................................................................................................................. 64 Table X3: Number of antimalarials audited........................................................................................................... 93 Table X4: Quality-Assured (QA ACT) and Non-Quality Assured ACTs....................................................................... 94 Table X5: Nationally Registered ACTs ................................................................................................................... 95 Table X6: Severe Malaria Treatment .................................................................................................................... 96 Table X7: Number of RDTs audited ...................................................................................................................... 97 Table X8: RDT Brand Names and Manufacturers* ................................................................................................. 98 Table X9: Adult Equivalent Treatment Dose Definitions........................................................................................108 www.ACTwatch.info Page 3 List of Figures Figure 1: Timeline of Key Events and Policies in Thailand......................................................................................... 6 Figure 2: Map of the selected areas*, Thailand 2016............................................................................................... 8 Figure 3: Survey flow diagram, Thailand, 2016........................................................................................................ 9 Figure 4. Outlet Survey Screening Flow Diagram, Thailand, 2016 ........................................................................... 10 Figure 5. Outlet type distribution, 2016................................................................................................................ 11 Figure 6. Market composition: antimalarial outlet type distribution, 2016 ............................................................. 12 Figure 7. Market composition: malaria blood testing outlet type distribution, 2016................................................ 12 Figure 8. Percentage of outlets with antimalarials in stock on the day of the survey by outlet type, 2016 ................ 13 Figure 9. Percentage of outlets with any antimalarial in stock on the day of the survey by outlet type by domain, 2016 .........................................................................................................................................................